Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKBIA | P25963 | 8/20 | 1.00 |
| ▸ | RELA | Q04206 | 8/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 0.71 |
| ▸ | SLC40A1 | Q9NP59 | 15/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414125 | 0.82 | SLC40A1 (1.00) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL11972877 | 0.78 | SLC40A1 (1.00) | NFKBIARELASLC40A1 | |
| SCHEMBL12474970 | 0.76 | SLC40A1 (0.63) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL11973718 | 0.74 | SLC40A1 (1.00) | NFKBIARELASLC40A1 | |
| SCHEMBL18434822 | 0.74 | SLC40A1 (0.72) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL11973677 | 0.73 | SLC40A1 (1.00) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL11997089 | 0.73 | SLC40A1 (0.78) | NFKBIARELASLC40A1 | |
| SCHEMBL11997112 | 0.72 | SLC40A1 (0.77) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL12475945 | 0.71 | SLC40A1 (0.64) | NFKBIARELAMMP2SLC40A1 | |
| SCHEMBL11973254 | 0.69 | SLC40A1 (1.00) | NFKBIARELASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | NFKBIA 1/4885RELA 10/4885MMP2 225/4885 |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | NFKBIA 1/4885RELA 10/4885MMP2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.